|| List of recent Vaccine-related patents
| Proliferating agent for monocyte, culture medium for proliferating monocyte, producing monocyte, producing dendritic cell, and producing dendritic cell vaccine|
The purpose of the present invention is to provide a means for proliferating a monocyte with high efficiency and in a simple manner. The present invention provides a proliferating agent for a monocyte, which consists of at least one component selected from flt-3l, il-3 and ifn-γ and can be used before a treatment for differentiation of a monocyte into a dendritic cell.
| Adjuvanted formulations of rabies virus immunogens|
The efficacy of rabies vaccines can be enhanced by adjuvanting rabies virus immunogens with a mixture of a tlr agonist (preferably a tlr7 agonist) and an insoluble metal salt (preferably an aluminium salt). The tlr agonist is typically adsorbed to the metal salt.
| Methods and compositions for stabilizing dried biological materials|
The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt.
| Trans-complementing, replication deficient lentiviral vectors and methods for making and using them|
The present invention relates to multiple novel approaches for the generation of an immune response in an animal, such as a human, using lentivirus-based vector technology. The invention provides for the ability to mimic the efficacy of a live attenuated (la) vaccine, without exposing the patient to the risk of disease as possible with some la vaccines.
| Baculovirus-based vaccines|
The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., hpv l1), enabling to function as a more efficient dna vaccine..
Kr Biotech Co., Ltd.
| Packaging of immunostimulatory substances into virus-like particles: preparation and use|
The invention relates to the finding that virus like particles (vlps) can be loaded with immunostimulatory substances, in particular with dna oligonucleotides containing non-methylated c and g (cpgs). Such cpg-vlps are dramatically more immunogenic than their cpg-free counterparts and induce enhanced b and t cell responses.
Cytos Biotechnology Ag
|Laser-based treatment for malaria|
Malaria, caused by the parasite plasmodium, is a devastating disease killing more than 800,000 people a year worldwide. Plasmodium replicates within erythrocytes by digesting hemoglobin, producing haemozoin as a byproduct which accumulates within the parasite.
|Xenoantigen-displaying anti-cancer vaccines and making|
Compositions, methods of making, and methods of using, xenoantigen-displaying anticancer vaccines are described. In another broad aspect, there is provided herein a method of synthesizing an alkynefunctionalized composition of claim 1, comprising: deprotecting an ester comprising a fmoc moiety to form a free acid; coupling the free acid of step (a) with an amine; and, removing the fmoc moiety, and coupling the remaining moiety with palmitic acid to yield an alkyne-functionalized composition..
The University Of Toledo
|Methods and compositions involving induced senescent cells for cancer treatment|
Disclosed are cancer vaccines comprising senescent cells and methods of using and preparing the vaccines.. .
The University Of Chicago
The invention provides flavivirus vaccines and methods of making and using these vaccines.. .
Sanofi Pasteur Biologics, Llc
Alphavirus vectors for respiratory pathogen vaccines
Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions..
Novartis Vaccines And Diagnostics, Inc.
Multivalent vaccine protection from staphylococcus aureus infection
Vaccine formulations effective against staphylococcus aureus, including methicillin-resistant staphylococcus aureus (mrsa) are disclosed, as well as methods of using the vaccine formulations in the treatment and prevention of staphylococcus aureus infections in a subject.. .
University Of Maryland, Baltimore
Stable anthrax vaccine formulations
Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided.
Emergent Biosolutions Inc.
Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide.
Takeda Vaccines, Inc.
Immunogenic compositions and reagents for preparing
The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.. .
Purdue Research Foundation
Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, co2, acid ph, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced tnf-α induction having a mutation in one or more lipid biosynthesis genes, including, but not limited to msbb, that are rendered stress-resistant by a mutation in the zwf gene.
Aviex Technologies Llc
Novel nicotine dna vaccines
The present invention provides dna-nanostructures comprising and at least one targeting moiety, wherein the at least one targeting moiety is linked to the dna-nanostructure; and wherein the at least one targeting moiety is nicotine or a nicotine analogue. These compounds elicit an immunogenic response in individuals and are useful as vaccines for ameliorating nicotine dependence..
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Ariz
Cholera toxin chimera and its use as a staph vaccine
The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from s.
Boise State University
Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersinia pestis as next generation plague vaccines
Techniques from two basic approaches, structure-based immunogen design and phage t4 nanoparticle delivery, are developed to construct new plague vaccines. The nh2-terminal β-strand of f1 of yersinia pestis is transplanted to the cooh-terminus of f1 of yersinia pestis and the nh2-terminus sequence flanking the β-strand of f1 of yersinia pestis is duplicated to eliminate polymerization but to retain the t cell epitopes.
The Catholic University Of America
Hcv vaccines and methods for using the same
Improved anti-hcv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus hcv genotype 1a/1b ns3 and ns4a.
Inovio Pharmaceuticals, Inc.
Rab6kifl/kif20a epitope peptide and vaccines containing the same
The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of seq id nos: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of seq id nos: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject.
Oncotherapy Science, Inc.
Adjuvant formulations comprising tlr4 agonists and methods of using the same
Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a tlr4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (hlb) of the emulsion is greater than about 9..
Infectious Disease Research Institute
Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule
The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula r1—xzszn—xzx—r2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.. .
Valneva Austria Gmbh
Methods and cells for the production of viral vaccines
The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.. .
Capsular gram-positive bacteria bioconjugate vaccines
The present invention encompasses a novel s. Aureus bioconjugate vaccine.
Kidney-specific tumor vaccine directed against kidney tumor antigen g-250
This invention provides an anti-cancer immunogenic agent(s) (e.g. Vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a g250 antigenic marker.
The Regents Of The University Of California
Treatment and prevention of gardnerella vaginalis infections
The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (vly) toxin from gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-vly antibodies and to their use therapeutically and in a new elisa assay of vly toxin.
The Trustees Of The University Of Columbia In The City Of New York
Recombinant virus-like particles encoded by multi-gene vector
The invention describes novel virus-like particles for use as vaccines, diagnostic tools and r&d tools based on recombinant dna and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts.
Plasmodium falciparum hla class i restricted t-cell epitopes
The invention relates immunogenic polypeptides and epitopes from plasmodium falciparum protein ama 1. The epitopes contain hla class i binding motifs and stimulate an anti-malaria cd8+ t-cell response.
Facilitator-dna combination vaccine
Provided herein is a vaccine that combines a vaccine facilitator and a dna construct encoding an antigen to elicit antigen-specific antibody responses, wherein the vaccine facilitator is a na/k pump inhibitor. Cellular entry of the dna is accelerated as compared to other vaccines that do not contain the vaccine facilitator..
Novel dna-origami nanovaccines
The present invention provides compositions comprising a dna-nanostructure and at least one targeting moiety, wherein the at least one targeting moiety is linked to the dna-nanostructure; and wherein the at least one targeting moiety is selected from the group consisting of antigens, aptamers, shrnas and combinations thereof, and methods of use thereof.. .
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Ariz
Liquid vaccines for multiple meningococcal serogroups
Conjugated capsular saccharides from meningococcal serogroups c, w135 and y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup a is added.
Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes il-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes il-12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed.
The Trustees Of University Of Pennyslvania
Soluble and membrane-anchored forms of lassa virus subunit proteins
Soluble and membrane-anchored forms of lassa virus (lasv) glycoprotein 1 (gp1), glycoprotein 2 (gp2), the glycoprotein precursor (gpc), the nucleocapsid protein (np), and the nucleic acids encoding these proteins are disclosed, as well as diagnostic and preventative methods using these compositions. Also disclosed are methods including preparation of vaccines, factors (e.g.
The Administrators Of The Tulane Educational Fund
Hla-dr binding peptides and their uses
The present invention provides hla-dr (mhc class ii) binding peptides derived from the ovarian/breast cancer associated antigens, human epidermal growth factor receptor 2 (her-2/neu), carcinoembryonic antigen (cea), insulin growth factor binding protein 2 (igfbp-2), and cyclin d1. The immunogenic peptides can be used in cancer vaccines..
University Of Washington
Influenza vaccines containing modified adenovirus vectors
This disclosure provides universal influenza vaccines which can provide extended protection for several years, provide improved protection to circulating influenza strains that were not predicted accurately for annual vaccine manufacturing, and provide protection against newly emerging strains of influenza virus which carry the potential for establishing global pandemics.. .
The Wistar Institute Of Anatomy And Biology
Vaccines against antigens involved in therapy resistance and methods of using same
Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject.
Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
Provided is an isolated mammalian negative strand rna virus, metapneumovirus (mpv), within the sub-family pneumoviridae, of the family paramyxoviridae. Also provided are isolated mammalian negative strand rna viruses identifiable as phylogenetically corresponding or relating to the genus metapneumovirus and components thereof.
Use of mtor inhibitors to enhance t cell immune responses
It is disclosed herein that treatment of a subject with an mtor inhibitor enhances antigen-specific t cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific t cell response in a subject by administering to the subject a therapeutically effective amount of an mtor inhibitor.
Adjuvant-sparing multi-dose influenza vaccination regimen
An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant..
Chimeric non-integrating lentiviral genomes as vaccines against hiv-1
Novel nucleic acids include non-integrative chimeric retroviral genomes including the 5′ and 3′ long terminal repeat sequences (ltrs) of the caprine lentivirus: the caprine arthritis encephalitis virus (caev) or of another retrovirus not integrating human cells and at least one viral gene of another retrovirus. A vector including such a nucleic acid, an immunogenic or vaccinal composition including the vector or the nucleic acid, as well as their use for treating and/or preventing an infection by a retrovirus or a disease induced by a pathogenic agent are also described..
Chengdu Boe Optoelectronics Technology Co., Ltd.
Vesicular stomatitis virus for prime boost vaccine
The present invention relates to vesicular stomatitis virus (vsv) matrix (m) protein mutants. One mutant m protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51).
The University Of Western Ontario
Multi-strain-reactive antibodies for therapy and diagnosis of influenza
The invention relates to a method for isolating a polypeptide reactive to influenza a hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza a hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza a subtypes of subtype group 1 and 2, to vaccines and uses thereof..
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (cmv) are disclosed. Subunit vaccines comprising a human cmv protein complex comprising pul128 or pul130, and nucleic acid vaccines comprising at least one nucleic acid encoding a cmv protein complex comprising pul128 or pul130 are described.
The Trustees Of Princeton University
Centrifuge vessels suitable for live cell processing and associated systems and methods
Centrifuge vessels suitable for live cell processing include a bowl with a cap, and a tube inside the bowl extending between the cap and a lower portion of the bowl. The bottom of the bowl can have a closed annular ring surrounding a center mound.
Recombinant negative strand virus rna expression systems and vaccines
The present invention relates to recombinant rna virus templates derived from and applicable to negative strand naturally non-segmented viruses, including the families bornaviridae, filoviridae, and paramyxoviridae, and methods for generating such recombinant rna virus templates, wherein the templates are generated from two or more recombinant rna molecules. The invention relates to the use of segmented recombinant rna virus templates for naturally non-segmented rna viruses to express heterologous gene products in appropriate host cell systems and/or to construct recombinant viruses taken from that family and that express, package, and/or present the heterologous gene product.
Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express egfr and gm3 n-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets.
Adjuvanted influenza virus compositions
The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant..
Viral attenuation and vaccine production
The present invention is directed to the generation of attenuated viruses or viral transcripts for the production of vaccines by incorporating microrna binding sites within the viral target sequence of the pathogen.. .
Combined influenza vaccines for seasonal and pandemic protection
Current approaches to influenza vaccination focus either on seasonal strains or pandemic strains. Current seasonal vaccines typically include antigens from two influenza a strains (h1n1 and h3n2) and one influenza b strain.
Method of treating pregnant cows and/or heifers
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (bvdv) for the the prophylaxis and treatment of bvdv caused infections. The invention also relates to a method of vaccinating a pregnant cow..
Mycobacterial vaccine vectors and methods of using the same
Mycobacterium bovis bcg is a potent stimulator of the cellular immune response and has potential as a recombinant vaccine vector. Disclosed are bcg strains that generate greater mhc class i presentation of a transgenic protein, relative to the unmutated parental strain, and that improve a recipient's cd8+ t cell response against the transgenic protein following vaccination.
Adjuvanted formulations of staphylococcus aureus antigens
The efficacy of s. Aureus vaccines can be enhanced by adjuvanting s.
Synthetic capsid proteins and uses thereof
The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic circovirus type capsid proteins with improved properties.
Tumor-specific gm-csf cytokine response as predictor of cancer vaccine effectiveness
The present invention relates to methods of treating cancer with a cancer vaccine using granulocyte-macrophage colony-stimulating factor (gm-csf) as a biomarker; methods of prognosticating an outcome of cancer treatment with a cancer vaccine using gm-csf as a biomarker; methods for qualifying subjects for cancer vaccination using gm-csf as a biomarker; methods for comparing the efficacy of two or more cancer vaccine treatments based on gm-csf response; and kits for the effective treatment of cancer.. .